Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,363.24 +650.96 (+1.04%) CMC Crypto 200
1,317.57 +40.59 (+3.18%)
Glenmark Pharmaceuticals Limited (GLENMARK.BO)
| Previous close | 1,060.50 |
| Open | 1,072.20 |
| Bid | 1,049.40 x 0 |
| Ask | 1,051.65 x 0 |
| Day's range | 1,046.40 - 1,072.20 |
| 52-week range | 550.50 - 1,098.00 |
| Volume | |
| Avg. volume | 43,348 |
| Market cap | 297.426B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -27.09 |
| Earnings date | 16 May 2024 - 30 May 2024 |
| Forward dividend & yield | 2.50 (0.24%) |
| Ex-dividend date | 18 Sept 2023 |
| 1y target est | 601.93 |
- Reuters
India's Glenmark Pharma posts Q2 loss on exceptional legal costs
India's generic drugmaker Glenmark Pharmaceuticals reported a loss in the second quarter, hurt by exceptional costs related to a legal settlement and higher expenses. Glenmark incurred an exceptional cost of 3.25 billion rupees, during the quarter, related to a legal case settlement with the U.S. Department of Justice, Antitrust Division and remediation costs at manufacturing sites in India and the United States. The branded formulations drugmaker, which focuses on dermatology, oncology and respiratory medication, said total revenue from operations rose 6.3% to 32.07 billion rupees, helped by growth in Europe and domestic businesses.
- Investing.com
Glenmark Pharma shares drop following major divestment of subsidiary
Shares of Mumbai-based Glenmark Pharmaceuticals fell 4.5% to Rs 790.25 on the National Stock Exchange (NSE) in early trade on Friday, following the company's announcement of a significant divestment in its subsidiary, Glenmark Life Sciences. The decline came after the stock reached a 52-week high of Rs 880 on Thursday.
